Kairos Pharma Statistics
Total Valuation
Kairos Pharma has a market cap or net worth of $20.17 million. The enterprise value is $17.09 million.
| Market Cap | 20.17M |
| Enterprise Value | 17.09M |
Important Dates
The last earnings date was Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Kairos Pharma has 12.85 million shares outstanding. The number of shares has increased by 2.97% in one year.
| Current Share Class | 12.85M |
| Shares Outstanding | 12.85M |
| Shares Change (YoY) | +2.97% |
| Shares Change (QoQ) | +3.29% |
| Owned by Insiders (%) | 59.89% |
| Owned by Institutions (%) | 0.35% |
| Float | 3.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.05 |
| P/TBV Ratio | 6.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.84, with a Debt / Equity ratio of 0.04.
| Current Ratio | 2.84 |
| Quick Ratio | 1.92 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.63 |
Financial Efficiency
Return on equity (ROE) is -375.74% and return on invested capital (ROIC) is -111.98%.
| Return on Equity (ROE) | -375.74% |
| Return on Assets (ROA) | -41.71% |
| Return on Capital (ROIC) | -111.98% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$913,667 |
| Employee Count | 3 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 1.54 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 47.73 |
| Average Volume (20 Days) | 92,824 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -1.99M |
| Pretax Income | -812,000 |
| Net Income | -2.74M |
| EBITDA | -1.83M |
| EBIT | -1.99M |
| Earnings Per Share (EPS) | -$0.26 |
Balance Sheet
The company has $3.22 million in cash and $142,000 in debt, giving a net cash position of $3.08 million or $0.24 per share.
| Cash & Cash Equivalents | 3.22M |
| Total Debt | 142,000 |
| Net Cash | 3.08M |
| Net Cash Per Share | $0.24 |
| Equity (Book Value) | 3.33M |
| Book Value Per Share | 0.26 |
| Working Capital | 3.07M |
Cash Flow
| Operating Cash Flow | -2.09M |
| Capital Expenditures | n/a |
| Free Cash Flow | -2.09M |
| FCF Per Share | -$0.16 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Kairos Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.97% |
| Shareholder Yield | -2.97% |
| Earnings Yield | -13.59% |
| FCF Yield | -10.34% |
Analyst Forecast
The average price target for Kairos Pharma is $9.00, which is 473.25% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.00 |
| Price Target Difference | 473.25% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |